重组水蛭素Ⅲ口服乳糜微粒的研究  

Studies on Oral Emulsionized Recombinant Hirudin Ⅲ

作　　者：汤沛霈[1] 常晓丹[1] 吴梧桐[1] 

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京210009

出　　处：《药物生物技术》2008年第6期458-461,共4页Pharmaceutical Biotechnology

基　　金：国家教育部博士学科点基金(20040316005)

摘　　要：为了实现重组水蛭素Ⅲ口服给药途径并验证其药效,将其制成乳糜微粒,比较了3种制备方法,确定了逆相蒸发法为r HV3乳糜微粒的最佳制备方法。优化了制备条件,通过正交实验确定了r HV3乳糜微粒配方,制得的r HV3乳糜微粒的包封率为(65.08±1.96)%。在-20℃保存条件下r HV3乳糜微粒稳定性良好。药效学实验结果表明,口服r HV3乳糜微粒具有良好的抗凝和抗栓作用。To make it possible that recombinant hirudinⅢ（rHV3） can be taken orally and to examine its pharmacodynamic action, we studied the emulsionized rHV3, and discussed three preparation methods, and the REV was fixed as the preparation method. The preparing conditions were optimized, and the directions for producing emulsionized rHV3 by orthogonal test were decided. The average encpsulation efficiency of the optimized emulsionized rHV3 was （65.08±1.96）%. It preserved more stabilization at -20℃. It can be seen that the emulsionized rHV3 has obvious anticoagulant and antithrombolic effect in the pharmacological test. So it could be developed to make a new antithrombotic drug.

关 键 词：重组水蛭素Ⅲ 乳糜微粒 制备方法 正交实验 稳定性 抗凝和抗栓 

分 类 号：Q51[生物学—生物化学]